NOS2 and familial pancreatic carcinoma: Klug and colleagues were pioneers in demonstrating that, in a preclinical model of pancreatic cancer, a single dose of LDRT (0.5-2 Gy) could reprogram immunosuppressive and pro-tumoural M2 TAMs into an antitumoural M1 phenotype characterized by elevated expression of inducible nitric oxide synthase (iNOS).